Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL trial
NL-OMON55418Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rifaximin and lactulose in hepatic encephalopathy (HE), sponsored by Amsterdam University Medical Center. Primary endpoint: Development of overt hepatic encephalopathy within 3 months after TIPS. Started Jan 2020; status: recruiting.
02
Drugs
rifaximinlactulose
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NL-OMON55418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55418.